Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene’s management team will host a conference call and webcast to discuss the results.
Conference Call and Webcast Details
A live audio webcast can be accessed by visiting the Investors section of the Company’s website on the Events page. An archived webcast will be available on the website approximately two hours after the event.
Source: Clene Inc.
Conference Luncheon - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press
Conference Boxed Lunches - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press
Continental Breakfast - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press